Drug Profile
BTG 1640
Alternative Names: ABIO-08/01; ABIO-0801; BTG-1640Latest Information Update: 21 Aug 2019
Price :
$50
*
At a glance
- Originator University of Reading
- Developer Abiogen Pharma
- Class Anxiolytics; Isoxazoles; Nootropics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Generalised anxiety disorder; Panic disorder
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 02 Aug 2010 ABIO 08/01 is still in phase II trials for Panic disorder in Italy
- 23 May 2008 Phase-II clinical trials in Panic disorder in Italy (PO)